stockrow
Monday 9 November 2026
Export KRRO’s income statement to Excel — free account
Korro Bio, Inc.
KRROKorro Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.4 million, up 181.5% from fiscal 2024.
- Revenue
- −86.3%
- EPS
- +61.0%
- Free cash flow
- +12.1%
Quarter to June 2026, against a year earlier
14.75
0.02
+0.14%
Follow KRRO
Alert me
Korro Bio, Inc. (KRRO) P/E ratio
Korro Bio, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| Jun 2025 | 0.0× | — |
| Mar 2025 | 0.0× | — |
| 8 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ACIU AC Immune compare | n/m |
| GLSI Greenwich LifeSciences, Inc. compare | n/m |
| FATE Fate Therapeutics, Inc. compare | n/m |
| CABA Cabaletta Bio, Inc. compare | n/m |
| ABEO Abeona Therapeutics Inc. compare | n/m |
| IMRX Immuneering Corporation compare | n/m |
| SLGL Sol-Gel Technologies Ltd. compare | n/m |
| KRRO Korro Bio, Inc. | n/m |
| VNDA Vanda Pharmaceuticals Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)